Signaling Inhibitors Accelerate the Conversion of mouse iPS Cells into Cancer Stem Cells in the Tumor Microenvironment by Du, Juan et al.
1Scientific RepoRtS |         (2020) 10:9955  | https://doi.org/10.1038/s41598-020-66471-2
www.nature.com/scientificreports
Signaling inhibitors Accelerate the 
conversion of mouse ipS cells into 
cancer Stem cells in the tumor 
Microenvironment
Juan Du1, Yanning Xu1,2, Saki Sasada1, Aung Ko Ko oo1, Ghmkin Hassan3,4, Hafizah Mahmud1, 
Apriliana cahya Khayrani1,5, Md Jahangir Alam1, Kazuki Kumon1, Ryo Uesaki1, 
Said M. Afify1,6, Hager M. Mansour1, neha nair1, Maram H. Zahra1, Akimasa Seno1,3,7, 
nobuhiro okada3, Ling chen2, ting Yan8 & Masaharu Seno1,3,7,9 ✉
Cancer stem cells (CSCs) are a class of cancer cells characterized by self-renewal, differentiation 
and tumorigenic potential. We previously established a model of cScs by culturing mouse induced 
pluripotent stem cells (miPSCs) for four weeks in the presence of a conditioned medium (CM) of cancer 
cell lines, which functioned as the tumor microenvironment. Based on this methodology of developing 
CSCs from miPSCs, we assessed the risk of 110 non-mutagenic chemical compounds, most of which are 
known as inhibitors of cytoplasmic signaling pathways, as potential carcinogens. We treated miPSCs 
with each compound for one week in the presence of a CM of Lewis lung carcinoma (LLC) cells. However, 
one-week period was too short for the CM to convert miPSCs into CSCs. Consequently, PDO325901 
(MEK inhibitor), CHIR99021 (GSK-3β inhibitor) and Dasatinib (Abl, Src and c-Kit inhibitor) were found to 
confer miPSCs with the CSC phenotype in one week. The tumor cells that survived exhibited stemness 
markers, spheroid formation and tumorigenesis in Balb/c nude mice. Hence, we concluded that the 
three signal inhibitors accelerated the conversion of mipScs into cScs. Similarly to our previous study, 
we found that the PI3K-Akt signaling pathway was upregulated in the CSCs. Herein, we focused on the 
expression of relative genes after the treatment with these three inhibitors. Our results demonstrated 
an increased expression of pik3ca, pik3cb, pik3r5 and pik3r1 genes indicating class IA PI3K as the 
responsible signaling pathway. Hence, AKT phosphorylation was found to be up-regulated in the 
obtained CSCs. Inhibition of Erk1/2, tyrosine kinase, and/or GSK-3β was implied to be involved in the 
enhancement of the PI3K-AKT signaling pathway in the undifferentiated cells, resulting in the sustained 
stemness, and subsequent conversion of miPSCs into CSCs in the tumor microenvironment.
Alexander A. Maximow, a Russian cell biologist, was the first who proposed the concept of stem cells in 19091. In 
1961, the two basic features defining stem cells, namely abilities of self-renewal and differentiation into mature 
cells, were uncovered by Till and McCulloch2. CSCs were first identified in the granulocytes of acute myeloid 
leukemia in 19943. Since 1997 when Bonnet and Dick identified the CSCs by the ability of self-renewal from 
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a heterogeneous tumor xenograft4, Studies have demonstrated that the CSCs exist in various types of cancers, 
including breast, brain, lung, gastric, colorectal cancers5. At present, CSCs represent a unique population of can-
cer cells that are tumorigenic and resistant to most chemotherapeutic agents and radiation therapy, supporting 
cancer progression and recurrence.
Recent reports have described that the plasticity of non-CSCs plays a crucial role in promoting the dynamic 
conversion of non-CSCs into CSCs, which exhibit hierarchical heterogeneity6–8. Although the factors involved 
in regulating the conversion have not been identified, epithelial-mesenchymal transition is closely related to the 
presence of CSCs. The phosphoinositide 3-kinase (PI3K), protein kinase B (AKT) and mammalian target of rapa-
mycin (mTOR), which constitutes the core cascade called the PI3K/AKT/mTOR signaling cascade, have regula-
tory roles in cell survival, proliferation, and differentiation, and a critical role in tumorigenesis9. PI3K is reported 
to be associated with the development of various human tumors, including breast cancer, lung cancer, melanoma 
and lymphomas10–14. Furthermore, the PI3K downstream kinase, AKT, is reported to be involved in malignant 
transformation15. In this context, some environmental factors could be important stimulants to understand the 
mechanism of conversion of non-CSCs to CSCs.
Some chemical compounds are well known as mutagens and/or carcinogens. Some as inhibitors of cytoplas-
mic signaling pathways and others as both mutagens and/or carcinogens and inhibitors. Chemical compounds 
are usually evaluated for their risk to induce cancer by various assays such as mutagenicity assays, repeated dose 
toxicity studies, and statistical analyses.
We have previously been investigating the new insight in the CSCs by developing a CSC model that is derived 
from iPSCs, which were reprogrammed from normal cells. CSCs are now widely considered as a small popu-
lation of cells present in malignant tumors exhibiting self-renewal and differentiation potential responsible for 
the malignancy. However, the mechanism of the appearance of CSCs is not well explained yet. Considering the 
microenvironment is crucial to regulate the proliferation, self-renewal potential and differentiation of normal 
stem cells or progenitor cells in each tissue, imbalanced abnormal microenvironment such as chronic inflam-
mation lasting a long time affecting on the plastic stem cells could be the stimulant to convert the normal stem 
cells into CSCs. In this context, microenvironment distorted by the factors secreted from cancer cells could 
affect the diverse directions of stem cells and lead to the characteristics of CSCs. Even though a CSC shares 
with normal stem cells in the characteristics of maintaining the stemness and differentiation potential, multiple 
genetic and epigenetic regulations are different to acquire the features of CSCs. The conversion of miPSCs into 
CSCs was demonstrated by the treatment with a CM prepared from different cancer cell lines, for a period of 
four weeks16–18. This implies that the essential factors should be contained in the CM derived from cancer cells 
mimicking the tumor microenvironment. In the current study, we proposed a simple method to assess the risks 
of tumor-inducing factors in the presence of chemical compounds that accelerated the conversion of miPSCs 
into CSCs. Furthermore, we used the signaling inhibitors to elucidate the signaling pathways responsible for the 
appearance of CSCs.
Materials and Methods
Materials. miPSCs, (iPS-MEF-Ng-20D-17; Lot No. 012) were provided by the RIKEN Cell Bank, Japan. 
DMEM, fetal bovine serum (FBS), 2-mercaptoethanol, collagenase, gelatin, Hematoxylin and Eosin Y were pur-
chased from Sigma, NY. EBM-2 media Endothelial cell basal medium-2 and EBM-2 SingleQuots Kit were from 
Lonza, MD, USA. Matrigel was from Corning Inc., Corning, NY, USA. KnockOut Serum Replacement (KSR) 
and Non-Essential Amino acids (NEAA) were from Gibco, NY. L-Glutamine, 2.5 % Trypsin and CaCl2 were 
from Nacalai Tesque, Japan. Paraformaldehyde, Hank’s balanced salt solution (HBSS) and 100 U/ml penicil-
lin/streptomycin (P/S) cocktail were from Wako, Japan. Leukemia Inhibitory Factor (LIF) was from Millipore, 
MA. Mitomycin C treated mouse embryonic fibroblasts (MEFs) were provided by Reprocell, Japan. Lewis lung 
carcinoma (LLC) cells were from ATCC, VA, USA. Insulin-transferrin-selenium-X (ITS-X) was from Life 
Technologies, CA. Signal transduction inhibitors used in this study were obtained as listed in Table S2.
Anti-mouse Ki67 rabbit polyclonal antibody (ab15580), anti-mouse Sox2 rabbit polyclonal antibody 
(ab97959) and anti-mouse panCK rabbit polyclonal antibody (ab191208) were purchased from Abcam, UK. 
Anti-mouse Erk1/2 (p44/42 MAPK) rabbit polyclonal antibody (4695), anti-mouse p-Erk1/2 (Thr202/Tyr204) 
rabbit polyclonal antibody (4370), anti-mouse Akt rabbit polyclonal antibody (9272), anti-mouse pAkt (Ser473) 
rabbit polyclonal antibody (9271), anti-mouse β-catenin rabbit polyclonal antibody (9562) , anti-mouse β-actin 
rabbit polyclonal antibody (4970), horseradish peroxidase (HRP)-conjugated anti-rabbit IgG goat polyclonal anti-
body (7074) or anti-mouse IgG goat polyclonal antibody (7076) were purchased from Cell Signaling Technology, 
MA, USA.
cell culture. The miPSCs were designed to express GFP gene under the control of Nanog promoter, so that the 
undifferentiated state is easy to distinguished from differentiated state19. The miPSCs were maintained in DMEM 
supplemented with 15% FBS, 0.1 mM NEAA, 2 mM L-Glutamine, 50 U/ml P/S, 0.1 mM 2-mercaptoethanol and 
1000 U/ml of LIF on feeder layers of mitomycin C treated MEF. In the case of feeder-free, miPSCs were cultured on 
gelatin-coated dishes. LLC cells were maintained in DMEM containing 10% FBS supplemented with 100 U/ml P/S.
For primary cultured cells, the mouse allografts were excised and cut into small pieces (approximately one mm3), 
then washed three times by HBSS and transferred them into a 15-ml tube contained with 4 ml of dissociation 
buffer, which was prepared as PBS containing 0.25% trypsin, 0.1% collagenase, 20% KSR, 1 mM of CaCl2, then 
incubated at 37 °C for 40 mins. Adding 5 ml of DMEM containing 10% FBS to terminate the digestion. The 
suspension of cells was transferred into the new tubes, centrifuged at 1000 rpm for five mins. The cell pellet was 
re-suspended in 5 ml HBSS, and centrifuged at 1000 rpm for five mins, then placed into an appropriate volume of 
miPS medium without LIF and seeded the cells into a dish at a density of 5 × 105/ml. For removing the host cells 
in primary cells should be treated with puromycin for 24 h.
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To prepare the CM from LLC cells, the medium was collected as previously described16. The mixture of 
CM and miPS medium (1:1) was supplemented with each signal inhibitor (Table S2). miPSCs were cultured in 
the mixed medium without LIF and MEF feeder cells. One half of the medium was replaced with fresh mixed 
medium every day, up to day 6. On day 7, the expression of green fluorescent protein (GFP) and cell morphology 
was observed, and photographed using an inverted fluorescent microscope (Olympus IX81, Japan).
Green fluorescent protein (GFP) Assay. miPSCs cells were seeded at a density of 2 × 103 cells/well in 
96-well black plates (Corning Inc., NY) using miPS medium overnight. On the second day, half of the medium 
was replaced with a fresh medium mixed with compounds every day, up to day six. On day seven, the cells were 
washed twice with 1× PBS and lysed in a 50 μl/well lysis buffer followed by the incubation at 37 °C for 5mins. 
The relative fluorescence intensity was then measured at 509 nm, excited at 488nm, using a microplate reader 
(SH-9000lab, Corona, Japan). The read of each well was obtained from 9 points at a distance of 1 mm from the 
bottom of each well flashed 30 times.
The GFP fluorescence from the miPSCs cultured in CM without signal inhibitors was used as a control to 
determine the threshold of the bottom line in order to distinguish the effect of the signal inhibitors. The fluores-
cence from 6 wells was measured 5 times from independent experiments, the averages and standard deviations of 
the readings were calculated (Table S1). Next, we assessed the effect of the inhibitors in concentrations between 0 
and 10 μM by the intensity of the GFP fluorescence and determined the optimal concentration which enhanced 
the fluorescence of GFP (Table S2).
Sphere formation assay. The cells were seeded at a density of 1 × 104 cells/well in 24-well ultra-low attach-
ment plates (Corning Inc., NY) in serum-free medium consisting of 97.5% DMEM, 0.5 U/ml P/S, 0.1 mM NEAA, 
1 mM L-Glutamine, 0.1 mM 2-mercaptoethanol and 1% v/v ITS-X. After 5 to 7 days, the number of spheroids 
was counted, and images were captured using an inverted microscope (CKX41, Olympus, Japan) or an inverted 
fluorescent microscope (IX81, Olympus, Japan).
tube formation assay. The cells were seeded at a density of 5 × 105 cells/60 mm dish and incubated at 37 
°C with 5% CO2. When the formation of a 70% confluent monolayer, collected and re-suspended 5 × 105 cells in 
EBM-2 media and seeded in 12-well plates, coated with growth factors reduced Matrigel for 24h in the presence 
of a different growth factors, such as human epidermal growth factor (EGF, 5 ng/mL), human vascular endothelial 
growth factor (VEGF, 0.5 ng/mL), R3-insulin-like growth factor-1 (R3-IGF-1, 20 ng/mL), ascorbic acid (1 μg/mL), 
hydrocortisone (0.2 μg/mL), human basic fibroblast growth factor (bFGF, 10 ng/mL), heparin (22.5 μg/mL) and 
2% FBS. Each experiment was performed in triplicate, and the images were captured by using an Olympus IX81 
microscope (Olympus, Tokyo, Japan).
Animal experiments. The animal experiments were reviewed and approved by the ethics committee for 
animal experiments at the Okayama University under the ID OKU-2016078. All experiments were performed 
according to the policy on the care and use of the laboratory animals, Okayama University. Thirty nude mice 
(Balb/c-nu/nu, female, four weeks) were purchased from Charles River (Kanagawa, Japan) and kept at 23 °C and 
fed with sterilized food and water during the experiments. Cells at 1 × 106 were suspended in 200 μl of HBSS and 
were subcutaneously transplanted into each mouse. Three mice were used for each inhibitor.
At the end of the experiments, the mice were euthanized by the isoflurane-euthanasia method (Laboratory 
Animal Anaesthesia (3rd Ed.) Paul A. Flecknell 2009). Five percent of isoflurane (DS Pharma Animal Health, 
Japan) was exposed to the mice and the exposure was continued until one minute after their breathing stopped. 
Finally, euthanasia was confirmed by cervical dislocation.
RNA extraction, cDNA synthesis and reverse transcription quantitative PCR analysis. Total 
RNA was extracted from cells with the RNAeasy Mini kit (QIAGEN, Germany) and one μg of RNA was 
reverse transcribed by the superscript first-strand kit (Invitrogen, CA). Reverse transcription-quantitative PCR 
(RT-qPCR) was performed with LightCycler 480 SYBR Green I Master Mix (Roche, Switzerland). The primers 
were described in Table S3.
Histological analysis and immunohistochemistry. For histological analysis, tumors were excised from 
the mice 4–6 weeks after transplantation. The paraffin-embedded tissue samples were cut into 5 μm-thickness 
sections, deparaffinized and stained with 0.5% Hematoxylin and Eosin Y (HE). The primary antibodies and 
dilutions used for IHC were as follows: 1:200 of anti-Ki67 antibody, 1:200 of anti-Sox2 antibody and 1:200 of 
anti-panCK antibody.
Western blotting. Proteins extracted from the miPSCs treated with each condition were subjected to 
SDS-PAGE, transferred to Immobilon-FL transfer membrane (PVDF, Merck Millipore, Germany) and probed 
with antibodies against Akt at a dilution of 1:1000, pAkt (Ser473) at a dilution of 1:1000, Erk1/2 at a dilution of 
1:1000, p-Erk1/2 (Thr202/Tyr204), at a dilution of 1:1000, β-catenin at a dilution of 1:1000 and β-actin at 1:1000. 
This was followed by the secondary antibody, either HRP–conjugated anti-rabbit or anti-mouse IgG at dilutions 
of 1:2000 or 1:5000, respectively.
Flow cytometry. miPSCs that survived following one week of treatment were transferred to a 60-mm dish 
and harvested during the logarithmic growth phase. Cells were re-suspended in 100 μl of ice-cold PBS and ana-
lyzed by a flow cytometer (BD Accuri C6 plus, Becton & Dickinson, NJ). Data from each experiment was ana-
lyzed by FlowJo software (FlowJo, LLC, Ashland, OR, USA).
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Statistical analysis. The data were analyzed by the two-tailed student’s t-test using the Prism Software 
version7 (Graph Pad Software, San Diego, CA, USA). Results are presented as the mean ± standard deviation 
(SD) from independent experiments. Each experiment was performed in triplicate. P < 0.05 was statistically 
significant.
ethics approval and consent to participate. The plan of animal experiments was reviewed and approved 
by the ethics committee for animal experiments of Okayama University under the ID: OKU-2016078 (2016).
Results
Evaluation of the effect of chemical compounds on the survival of miPSCs. Previously, we have 
described the development of CSCs from miPSCs using CM from cancer cell lines, during a 4 week or longer 
period16–18. Based on these previous experiments, we treated the miPSCs with each compound for 1 week in 
a CM of Lewis lung carcinoma (LLC) cells. However, 1 week was too short a period for the CM to induce the 
conversion of the miPSCs into CSCs (Fig. 1a). We postulated that the short time required to assess the develop-
ment of CSCs from miPSCs could be utilized to evaluate non-mutagenic chemical compounds mediating the 
conversion of miPSCs to CSCs. To establish this procedure, we adopted miPSCs expressing a gene encoding the 
green fluorescent protein (GFP) under the control of Nanog promoter16 to monitor the potential of stemness by 
green fluorescence under a microscope or using a microplate reader. This procedure roughly distinguished the 
conditions that enhanced the survival of miPSCs, including the conversion into CSCs, by the expression of GFP 
Figure 1. The conversion of miPSCs into CSCs by the treatments with chemical compounds. (a) Schematic 
flow chart of the conversion from miPSCs into CSCs by chemical compounds. (b) Representative images of the 
conversion from miPSCs into CSCs. Cells were cultured with media containing CM and chemical compounds, 
and colonies were observed for the GFP expression after 1-week treatment.
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fluorescence. Following a 1-week treatment, the GFP fluorescence of miPSCs persisted during the undifferenti-
ated state, while GFP fluorescence decreased when the miPSCs normally differentiated to die in the absence of 
Leukemia Inhibitory Factor (LIF). We evaluated the effect of compounds in the conversion of miPSCs into CSCs 
Figure 2. Positive chemical compounds promote self-renewal capacity in the conversion of miPSCs into CSCs. 
(a) Sphere formation assay shows spherogenic potential and the expression of GFP. (b) Graphical representation 
of the number of spheroids after the conversion of 1-week. (c) Flow cytometric analysis shows GFP positive 
population in the conversion cells after treatment with chemical compounds. (d) The expression levels of 
stemness markers (endogenous genes) were analyzed by RT-qPCR. The data were analyzed using ordinary 
one-way ANOVA multiple comparisons and is presented as the mean ± standard deviation ****P < 0.0001, 
***P < 0.001, **P < 0.01, *P < 0.05.
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in the presence of a CM derived from LLC cells. We found certain compounds enhanced the expression of GFP 
in miPSCs while some decreased, and others gave no significant effect (Fig. 1b). Subsequently, we evaluated each 
of the 110 candidate compounds to establish the threshold and optimal concentration by detecting the intensity 
of GFP fluorescence (Tables S1 and S2).
Stemness and differentiation of GFP positive miPSCs after 1-week treatment. Previous evi-
dence suggests that the ability to form spheroids is associated with CSCs properties20. GFP-positive cells that 
survived following one week of treatment were further assessed for the sphere-forming potential. We assessed 
the chemical compounds, which exhibited positive capability to the cell survival following 1-week treatment 
(Table S2), for sphere formation potential in suspension culture. Our results indicated that six compounds pro-
moted sphere formation (Fig. 2a,b), while the remaining candidate compounds failed to demonstrate this prop-
erty. The surviving cells were then cultured under adhesive conditions and analyzed by flow cytometry, with 
approximately 60–80% of the cells expressing GFP (Fig. 2c).
We assessed the expression of endogenous stemness markers Oct3/4, Sox2, Nanog, Klf4 and c-Myc, which have 
a dominant role in the maintenance of embryonic stem cells (ESCs) and iPSCs, and self-renewal in the surviv-
ing cells, using RT-qPCR. The expression level of each endogenous gene and transgene was confirmed by using 
specific primers21. The expression of stemness markers, Oct3/4, Sox2 and Nanog, was significantly upregulated 
in miPSCs when treated with PD0325901, CHIR99021 and Dasatinib (Fig. 2d). However, the cells treated with 
Masitinib did not show significance difference in the expression of both oct3/4 and sox2 but only Nanog was 
upregulated. As for the expression of Klf4 gene, PD0325901, CHIR99021 and Dasatinib maintained almost at 
the same level of miPSCs while Masitinib decreased the expression. That of c-Myc gene was suppressed in every 
treatment. We did not detect any aberrant activation of the transgene, pertinent to viral-transduction for the 
establishment of miPSC. Since PD0325901, CHIR99021 and Dasatinib feasibly enhanced the sphere formation 
and the expression of the stemness marker. The amount of Nanog and Oct3/4 increased in miPSCs when treated 
with these three compounds. Collectively, PD0325901, CHIR99021 and Dasatinib were confirmed to maintain 
the stemness of miPSCs and the resultant cells were designated as miPS-LLCcm-PD, miPS-LLCcm-CH and 
miPS-LLCcm-Da, respectively.
The differentiation potential of the treated cells was evaluated by tube formation exhibiting the phenotype of 
endothelial cells (Fig. S1). Also, miPSCs were cultured in adhesive condition without LIF (Fig. S2). As the result 
of differentiation, cells lost GFP expression after 3 days and died after 1 week due to cell senescence.
Tumorigenicity of GFP positive miPSCs after 1-week treatment. Considering the self-renewal 
capacity of these cells, and the results from our previous study, we investigated whether these compounds were 
effective in promoting the conversion from miPSCs into CSCs. To evaluate the tumorigenicity of these cells, 
1 × 106 of these cells were subcutaneously transplanted into Balb/c nude mice, and the tumor formation was 
monitored for 6 weeks (Fig. 3a). Tumors formed were excised at 6-weeks (Fig. 3b) and subjected to histological 
and immunohistochemical analysis (Fig. 4). As previously reported16, miPSCs formed a teratoma phenotype 
with various normal germ layers, including the squamous epithelium (keratinized ball), skeletal muscle, cartilage 
and benign glandular epithelium (Fig. 4a). Tumors derived from miPSCs treated with PD0325901, CHIR99021 
and Dasatinib formed malignant tumors, sections of which demonstrated poorly differentiated phenotype, high 
nuclear to cytoplasmic ratio, severe nuclear atypia and multiple pathological mitotic figures (Fig. 4b–d). They 
also exhibited multiple abnormal glands, trabecular patterns, necrosis in the glandular cavity, and large zones of 
Figure 3. Tumorigenicity of CSCs converted from miPSCs treated with chemical compounds. (a) The tumor 
growth in 6 weeks. (b) Generation of tumors after subcutaneous transplantation of miPSCs and the 1 week of 
converted cells.
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Figure 4. Histopathological observation of the tumors formed by the CSCs. Benign teratoma formed by 
miPSCs. (a) transplanted subcutaneously. Normal tissue types derived from three germ layers, including 
squamous epithelium (keratinized ball), skeletal muscle, cartilage and benign glandular epithelium are 
observed. Sections from the tumors formed by miPS-LLCcm-PD (b) miPS-LLCcm-CH (c) and miPS-
LLCcm-Da (d) cells transplanted subcutaneously. Malignant structures are observed in the glandular cavities 
(square, bottom right in b) composed of multiple abnormal glands, which are crowded back to back exhibiting 
high nuclear to cytoplasmic ratio, severe nuclear atypia and multiple pathological mitotic figures (asterisks in 
b–d). Abnormal glands, inside of glandular cavity has necrosis (arrow in c), and large area necrosis (oval in c). 
Original magnification was 20X and 40X (a–d). (e) Immunohistochemical analysis showed malignancies with 
highly proliferative areas strongly stained for Ki-67 and poorly differentiated areas, poorly stained for CK and 
strongly for Sox2 in the tumor formed by miPS-LLCcm-PD, miPS-LLCcm-CH and miPS-LLCcm-Da when 
compared with the benign teratoma formed by miPSCs.
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necrosis in the mesenchymal tissue. Immunohistochemical analysis demonstrated that the staining with Ki-67 
antibody was highly proliferative, supporting the rapid tumor growth. The expression of CK and Sox2 indicated 
phenotypes of poor differentiation (Fig. 4e). Hence, the development of malignant tumors was confirmed by the 
GFP positive miPSCs treated with the inhibitors for one week (Table 1).
Self-renewal and stemness capacities of primary cells derived from tumors. To further evaluate 
the properties of primary tumors, the primary cells were cultured from the tumors developed in the previous 
section. The adhesive culture of the primary cells was positive for GFP, indicating that they originated from the 
miPSCs (Fig. 5a). In suspension culture, these cells were able to form spheroids indicating the self-renewal capac-
ity, and all spheroid-forming cells expressed GFP (Fig. 5b). The expression levels of Oct3/4, Sox2, Nanog, and 
Klf4 were relatively maintained or slightly enhanced in the primary cells when compared with miPSCs (Fig. 5c). 
However, the expression of c-Myc was decreased, suggesting a negligible contribution of this gene to the conver-
sion of miPSC to CSC. Therefore, endogenous Oct3/4, Nanog, Sox2 and Klf4 might contribute to these properties. 
We further evaluated the expression of CSC markers, CD44 and CD133 in primary cultured cells. These markers 
found increased in treated cells when compared with those in miPSCs.
Signaling inhibitors accelerated the conversion of miPSCs into CSCs activating the PI3K-AKT 
pathway. The primary cultured cells obtained from the malignant tumors developed by transplanting miPSCs 
treated with PD0325901, CHIR99021 and Dasatinib were named as miPS-LLCcm-PDpr, miPS-LLCcm-CHpr, 
miPS-LLCcm-Dapr, respectively. The signaling pathways of Ras-Raf-MEK-ERK, Abl, Src, c-Kit, Wnt-GSK3 and 
PI3K-Akt-mTOR are considered typically important in cancer cell growth and survival22–24. Our results demon-
strated that the inhibition of the pathways, expect PI3K, was effective in enhancing the induction of the CSCs. 
On the other hand, PI3K inhibitors did not enhance the induction of CSCs (Table S2). Furthermore, in our 
previous study, we reported that PI3K-AKT signaling pathway was up-regulated in the CSCs developed from 
miPSCs25. Therefore, we evaluated the expression of PI3Ks in the CSCs, developed from miPSCs, in the presence 
of PD0325901, CHIR99021 and Dasatinib. Simultaneously, the expression of PTEN, which is considered to be 
antagonized by PI3K through the dephosphorylation of PIP326, was evaluated. We assessed the expression of 
Pik3ca, Pik3cb, Pik3cg, Pik3r1, Pik3r5, Pik3r6 and PTEN using RT-qPCR in the primary cultured cells (Fig. 6a). 
In the comparison to the miPSCs, Pik3ca, Pik3cb, Pik3r1 and Pik3r5 showed significantly higher expression in 
the miPS-LLCcm-PDpr, miPS-LLCcm-CHpr and miPS-LLCcm-Dapr cells while PTEN showed lower expres-
sion, and Pik3cg and Pik3r6 demonstrated no expression. We then confirmed the expression of AKT1, AKT2 
and mTOR using RT-qPCR (Fig. S3). We assessed the phosphorylation of AKT by western blotting (Fig. 6b) and 
found that the phosphorylation was enhanced in miPS-LLCcm-PDpr, miPS-LLCcm-CHpr, miPS-LLCcm-Dapr 
cells when compared with miPSCs. The western blotting of β-catenin, Erk1/2 and phosphorylated Erk1/2 showed 
inhibition or decrease of phosphorylation of Erk1/2 in the cells treated with chemicals while the amount of 
β-catenin was not apparently affected (Fig. 6c). These findings are consistent with the enhanced PI3K-AKT sign-
aling pathway in CSCs, as demonstrated in our previous study25.
Discussion
The carcinogenic risk assessment of chemical compounds has always been performed by different procedures 
such as mutagen tests, repeated dose toxicity studies, and statistical analyses. Since these procedures are consid-
ered to involve oncogenic mutations, it takes a long time to assess the risks. However, few rapid methods to eval-
uate the carcinogenic risk of non-mutagenic chemical compounds are found. In this study, we proposed a simple 
and feasible method for preliminary screening of carcinogens. Based on the previous reports on the induction 
of CSCs16–18, we exploited miPSCs expressing GFP under the control of the Nanog promoter19. It is worthwhile 
noticing that the miPSCs were reprogrammed from normal embryonic fibroblasts, but not from cancer-derived 
cells. Since Nanog was considered as a marker widely associated with stemness27,28, the assessment procedure was 
designed to observe GFP in the miPSCs under TME for 1-week, which was not long enough to induce sufficient 
oncogenic mutations, in the presence of each chemical compound. One hundred and ten non-mutagenic chem-
ical compounds, most of which were known as inhibitors of cytoplasmic signaling pathways, were applied on 
Supplement
Conditioned 
medium
Cell 
number
Tumor 
formation Histologic examination
LIF (1000U/mL) − 1 × 106 3/3 Benign teratoma
− + 1 × 106 0/3 −
Mastinib (6.25 μM) + 1 × 106 0/3 −
PD0325901 (5 μM) + 1 × 106 3/3 Malignant tumor, adenocarcinoma
CHIR99021 (2.5 μM) + 1 × 106 3/3 Malignant tumor, adenocarcinoma
Rabastinib (2.5 μM) + 1 × 106 0/3 −
ALK5 Inhibitor (10 μM) + 1 × 106 0/3 −
Dasatinib (1.25 μM) + 1 × 106 3/3 Malignant tumor, adenocarcinoma
Imatinib (2.5 μM) + 1 × 106 0/3 −
Ponatinib (0.625 μM) + 1 × 106 0/3 −
Table 1. Summary of tumorigenic potential of miPSCs treated in various conditions.
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the procedure to assess their risk of inducing CSCs. Twenty out of 110 compounds exhibited GFP fluorescence 
significantly maintained or enhanced in miPSCs. After evaluating the colony-forming efficiency, we selected eight 
chemical compounds. Further, sphere formation, which contributes to self-renewal to maintain stemness, was 
successful to select six out of these eight compounds. Finally, three compounds, PD0325901, CHIR99021 and 
Dasatinib, were found to facilitate tumor formation in vivo. The resultant cells exhibit the spheroid formation in 
the suspension culture and high tumorigenic potential as the basic characteristics of CSCs29–31, so we concluded 
Figure 5. Primary culture cells possess self-renewal capacity. (a,b) Primary cells in adherent culture and 
sphere formation in suspension culture with the expression of GFP. (c) RT-qPCR analysis of stemness markers 
in primary tumor cells. The data were analyzed using ordinary one-way ANOVA multiple comparisons and 
presented as the mean ± standard deviation ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05.
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that miPSCs were converted into CSCs. Although PD0325901, CHIR99021 and Dasatinib are considered to sup-
press the growth of cancer cells as anti-cancer agents, we found in this study these compounds might be inducing 
CSCs under the TME. These results could help find some mechanisms to explain the resistance of CSCs against 
chemotherapy in the future.
Dasatinib is a known tyrosine kinase inhibitor of ABL1/BCR-ABL1, whereas Masatinib as c-Kit. Interestingly, 
miPSCs treated with Masatinib were not tumorigenic and Masatinib was not indicated as an inducer of CSCs 
in this study. As c-Kit is known as the Stem Cell Factor receptor, Masatinib could have inhibited the signaling 
pathway essential for the self-renewal. On the other hand, Dasatinib might inhibit the growth of certain cells at 
partially differentiated stages, resulting in the enhancement of self-renewal of the undifferentiated cells. These 
results may imply the different functions of tyrosine kinases involved in the stages of cellular differentiation.
PD0325901 is well known as a MEK1/2 inhibitor. MEK is a main downstream tyrosine kinase from the Ras/
Raf/MAP kinase cascade32, and PD0325901 appeared to conceivably induce the conversion of miPSCs to CSCs, 
as Dasatinib did.
CHIR99021 is an inhibitor of GSK-3β, which plays a role in the downstream signaling of Wnt. As Wnt sup-
presses the function of GSK-3β, CHIR99021 could act as Wnt resulting in the activation of β-catenin-Lef/Tcf sig-
naling, considered necessary to maintain CSCs33–35. Ying et al. reported that the self-renewal potential of mouse 
ESCs was maintained in the presence of CHIR99021 and PD032590136. In this context, down-modulation of 
GSK-3β could result in a crucial stage to maintain metabolic activity, biosynthetic capacity, and overall viability, 
resulting in the decrease of phospho-ERK through the attenuation of MEK1/2, which reversed, would support 
our results. Hence, these inhibitors appear to relatively activate the PI3K/AKT pathway.
Recently, we have found the overexpression of pik3r5 and pik3cg, components of class IB PI3 kinase, in CSCs 
derived from miPSCs cultured in the presence of CM25. We could postulate again that the PI3K/AKT pathway 
might be activated in miPS-LLCcm-PD, miPS-LLCcm-CH, miPS-LLCcm-Da cells, which were resulted from the 
1-week treatment in this study. The western blotting analysis detected a significant amount of immunoreactive 
PI3K and phosphorylated AKT in the primary cultures derived from transplanted tumors (Fig. 6b). In accordance 
with the results obtained, we further investigated the expression levels of each moiety of PI3K, namely Pik3ca, 
Pik3cb, Pik3cg, Pik3r1, Pik3r5 and Pik3r6. We found the overexpression of Pik3ca, Pik3cb, Pik3r1 and Pik3r5 
as the candidates for further evaluation. Pik3r1and Pik3ca/Pik3cb are the components of class IA PI3K while 
Pik3r5, a moiety of class IB, was found in our previous report25. The expression of Pik3cg, the half moiety of class 
Figure 6. PI3K signaling pathway was activated in primary culture cells. (a) rt-qPCR analysis of Pik3ca, Pik3cb, 
Pik3cg, Pik3r1, Pik3r5, Pik3r6 and PTEN expression. (b) Western blotting analysis of the AKT expression and 
phosphorylation. (c) Western blotting analysis of the β-catenin, Erk1/2 and phosphorylated Erk1/2.
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IB for Pik3r5, was too low to be amplified by RT-qPCR, and hence class IB PI3K was not considered as active. 
Moreover, the combination of Pik3r1 and Pik3ca formed PI3K that is activated through tyrosine kinase receptors 
and Pik3r1 and Pik3cb formed PI3K that is activated by receptor tyrosine kinases and/or G Protein-Coupled 
Receptors (GPCRs). Therefore, the resultant CSCs could acquire a variety of potential critical features in mediat-
ing several aspects of cellular function, including nutrient uptake, metabolic reactions, cell growth and survival 
through PI3K/AKT signaling pathways in response to various ligand stimulation. This analogy may coincide 
with the several previous studies demonstrating PI3K and AKT were frequently hyper-activated in a majority 
of cancers37,38 while the mechanisms by which PI3K regulated self-renewal and pluripotency, remain somewhat 
elusive. However, the contribution of PI3K/AKT signaling in preserving the ability of iPSCs to self-renewal and 
differentiation has been delineated in recent studies39,40.
Hishida et al. suggested that PI3K promoted the retention of ES cell properties mainly through the inhibition 
of the two downstream pathways, the mitogen-activated protein kinases/extracellular signal-regulated kinase 
(MAPK/Erk) pathway and the GSK3 signaling pathway33. It is worthwhile noticing that the phosphorylation of 
Erk was inhibited by the treatment with CHIR99021 (GSK-3β inhibitor) and Dasatinib (Abl, Src and c-Kit inhibi-
tor) as well as PDO325901 (MEK inhibitor) due to probably by the crosstalk of the signaling (Fig. 6c). This obser-
vation could be supported by the down-regulation of c-Myc (Fig. 2d), which coincided with the results reported 
by Maranpon et al.41. Simultaneously, the effect of GSK-3β inhibitor was not apparent on the amount of β-catenin 
as found in Fig. 6c probably because all the cells were maintaining the stemness, which was considered to be sup-
ported by the Wnt signaling. The crosstalk mechanism in this point should be further investigated in the future. 
Previous studies from several groups have demonstrated that certain AKT downstream factors, such as Oct3/4, 
Sox2 and Nanog, played an important role in the self-renewal of ESCs and the early development of embryos42–44. 
Meanwhile, these markers were also found as the targets of the AKT signaling pathway phosphorylating T235 in 
Oct4, to maintain stemness and inhibit the differentiation of iPSCs45. The enhanced conversion of the iPSCs into 
CSCs could be explained similarly.
conclusions
miPSCs expressing the GFP gene under the control of the Nanog promoter were exploited to screen the car-
cinogens in 1 week under TME. As the results showed, PDO325901, CHIR99021 and Dasatinib were found to 
enhance the induction of CSCs. Taking the signaling pathways inhibited by these compounds into consideration, 
the inhibition of Erk1/2, tyrosine kinase and/or GSK-3β were implied to be involved in the enhancement of the 
PI3K-AKT signaling pathway, resulting in the sustained stemness and exerting tumorigenic potential in miPSCs 
under TME.
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